GILD
Gilead Sciences

Conference date: February 6, 2024 @ 2:00 PM Pacific Time

Gilead: A Hold Despite Cancer Advance, Remdesivir, Dividend [Seeking Alpha, March 11, 2021]

Gilead Sciences Is A Buy Despite Flat 2020 Guidance [Seeking Alpha, February 12, 2020]

Earlier articles are below the summaries table.

William P. Meyers Analyst Conference summaries available:

2023
Gilead GILD analyst conference call Q1 2023 Gilead GILD analyst conference call Q2 2023 Gilead GILD analyst conference call Q3 2023 Gilead GILD analyst conference call Q4 2023
April 27, 2023 August 3, 2023 Nov. 7, 2023 Feb. 6, 2024
Q1 2023 Q2 2023 Q3 2023 Q4 2023
2022
Gilead GILD analyst conference call Q1 2022 Gilead GILD analyst conference call Q2 2022 Gilead GILD analyst conference call Q3 2022 Gilead GILD analyst conference call Q4 2022
April 28, 2022 August 2, 2022 Oct. 27, 2022 Feb. 2, 2023
Q1 2022 Q2 2022 Q3 2022 Q4 2022
2021
Gilead GILD analyst conference call Q1 2021 Gilead GILD analyst conference call Q2 2021 Gilead GILD analyst conference call Q3 2021 Gilead GILD analyst conference call Q4 2021
April 29, 2021 July 29, 2021 Oct. 28, 2021 Feb. 1, 2022
Q1 2021 Q2 2021 Q3 2021 Q4 2021
2020
Gilead GILD analyst conference call Q1 2020 Gilead GILD analyst conference call Q2 2020 Gilead GILD analyst conference call Q3 2020 Gilead GILD analyst conference call Q4 2020
April 30, 2020 July 30, 2020 Oct. 28, 2020 Feb. 4, 2021
Q1 2020 Q2 2020 Q3 2020 Q4 2020
2019
Gilead GILD analyst conference call Q1 2019 Gilead GILD analyst conference call Q2 2019 Gilead GILD analyst conference call Q3 2019 Gilead GILD analyst conference call Q4 2019
May 2, 2019 July 30, 2019 Oct. 24, 2019 Feb. 4, 2020
Q1 2019 Q2 2019 Q3 2019 Q4 2019
2018
Gilead GILD analyst conference call Q1 2018
Gilead GILD analyst conference call Q2 2018
Gilead GILD analyst conference call Q3 2018
Gilead GILD analyst conference call Q4 2018
May 1, 2018
July 25, 2018
Oct. 25, 2018
Feb. 04, 2019
Q1 2018
Q2 2018
Q3 2018
Q4 2018
2017
Gilead GILD analyst conference call Q1 2017
Gilead GILD analyst conference call Q2 2017
Gilead GILD analyst conference call Q3 2017
Gilead GILD analyst conference call Q4 2017
May 2, 2017
July 26, 2017
 Oct. 26, 2017
February 6, 2018
Q1 2017
Q2 2017
Q3 2017
Q4 2017
2016
Gilead GILD analyst conference call Q1 2016
Gilead GILD analyst conference call Q2 2016
Gilead GILD analyst conference call Q3 2016
Gilead GILD analyst conference call Q4 2016
04/28/2016
07/25/2016
11/01/2016
02/07/2016
Q1 2016
Q2 2016
Q3 2016
Q4 2016
2015
Gilead GILD analyst conference call Q1 2015
Gilead GILD analyst conference call Q2 2015
Gilead GILD analyst conference call Q3 2015
Gilead GILD analyst conference call Q4 2015 on February 2, 2016
04/30/2015
 07/28/2015
10/27/2015
02/02/2016
Q1 2015
Q2 2015
Q3 2015
Q4 2015
2014
Gilead GILD analyst conference call Q1 2014
Gilead GILD analyst conference call Q2 2014
Gilead GILD analyst conference call Q3 2014
Gilead GILD analyst conference call Q4 2014
04/22/2014
07/23/2014
10/28/2014
02/03/2015
Q1 2014
Q2 2014
Q3 2014  
Q4 2014
2013
Gilead GILD analyst conference call Q1 2013
Gilead GILD analyst conference call Q2 2013
Gilead GILD analyst conference call Q3 2013
Gilead GILD analyst conference call Q4 2013
05/02/2013
07/25/2013
10/29/2013 
02/04/2014 
Q1 2013
Q2 2013
Q3 2013
Q4 2013  
2012
Gilead GILD analyst conference call Q1 2012
Gilead GILD analyst conference call Q2 2012
Gilead GILD analyst conference call Q3 2012
Gilead GILD analyst conference call Q4 2012
04/26/2012
07/26/2012
10/23/2012
02/04/2013
Q1 2012
Q2 2012 
Q3 2012
Q4 2012
2011
Gilead GILD analyst conference call Q1 2011
Gilead GILD analyst conference call Q2 2011
Gilead GILD analyst conference call Q3 2011
Gilead GILD analyst conference call Q4 2011
04/20/2011
 07/26/2011
10/27/2011 
02/02/2012
Q1 2011
 Q2 2011
Q3 2011
Q4 2011
2010
Gilead GILD analyst conference summary Q1 2010
Gilead GILD analyst conference summary Q2 2010
Gilead GILD analyst conference call Q3 2010
Gilead GILD analyst conference call Q4 2010
4/20/2010
07/20/2010 
 10/19/2010
01/25/2011 
Q1 2010
Q2 2010  
Q3 2010  
Q4 2010  
2009
Gilead analyst conference summary Q1 2009
Gilead GILD analyst conference summary Q2 2009
Gilead GILD analyst conference summary Q3 2009
Gilead GILD analyst conference summary Q4 2009
04/21/2009
 07/21/2009
 10/20/2009
 01/26/2010
Q1 2009
Q2 2009  
Q3 2009  
 Q4 2009
2008
Gilead Q1 2008 analyst conference summary
Gilead analyst conference summary Q2 2008
Gilead analyst conference summary q3 2008
Gilead Sciences Q4 2008 analyst conference cummary
04/16/2008
07/17/2008
10/16/2008
01/27/2009
Q1 2008
Q2 2008
Q3 2008
Q4 2008
2007
Gilead Q4 2007 analyst conference summary
Gilead Q3 analyst conference summary
GILD Q2 2007
GILD conference
01/23/2008
10/18/2007
7/19/2007
4/18/2007
Q4 2007
Q3 2007
Q2 2007
Q1 2007

Gilead Sciences Deal With Galapagos NV Should Be A Winner [Seeking Alpha, September 2, 2019]

Galapagos NV Osteoarthritis Drug Candidate Has Vast Potential Value [Seeking Alpha, August 26, 2019]

Gilead Sciences At The Filgotinib And Selonsertib Crossroads [Seeking Alpha, May 9, 2019]

Gilead Q2 Results Could Initiate A Rally [Seeking Alpha, July 9, 2018]

Gilead Sciences Going Down When It Should Go Up [Seeking Alpha, 12/8/2017]

Gilead Sciences Q1 2016 Key Insights [May 3, 2016 at Seeking Alpha]

Wider Reach Is Sought for Costly New Hepatitis C Treatments [Aug. 25, 2015, New York Times]

Gilead Sciences: P/E and Pipeline Beyond HCV [June 9, 2015 at Seeking Alpha]
Could GlaxoSmithKline Be a Better Investment Than Gilead? [September 17, 2014 at Seeking Alpha]
The Solid Gold Wonder Drug [September 2014 Scientific American]
Gilead Down on Merck-Idenix Deal, But Little to Fear [June 9, 2014 at Seeking Alpha]
FDA Approves Zydelig (idelalisib) for CLL, FL, and SLL [July 23, 2014 Gilead press release]
Gilead Sciences Hepatitis C Approval May Be Factored In [July 30, 2013]
Gilead Sciences Pipeline Remains Undervalued [December 3, 2012]
Gilead Sciences, Biogen Idec, and Celgene [August 13, 2012]
Gilead Sciences Looks for Hepatitis C Cure [April 29, 2012]
Gilead Sciences Readies Pipeline [July 27, 2011]
Gilead Sciences, Antivirals, and Tamiflu [January 26, 2011]
Gilead Sciences Rebuilds Pipeline Optimism [October 24, 2010]
Gilead Sciences (GILD) Q2 Outlook [July 6, 2009]
Gilead (GILD) Thrives Despite Downturn [October 21, 2008]
Aztreonam Lysine Rejected by FDA [September 20, 2008]
Gilead Should Rise on Penetration, Viread [September 10, 2008]
Gilead Preps for Atripla in Europe [January 24, 2008]
Choosing a Biotech Stock 2: Gilead [September 10, 2007]

Gilead is a biotechnology pharmaceutical company; products include Atripla, Truvada, and Sovaldi. So far it has specialized in anti-viral agents for HIV, Hepatitis B, and Hepatitis C as well as cancer and cardiovascular therapies.

I own this stock

Gilead Sciences Web site:

Gilead Sciences main page
Gilead Sciences investor page

Disclaimer: My analyst summaries may include both my condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2024 William P. Meyers